RxDoctor Payments Data

Eileen Wang, MD

Ophthalmology · Lawrenceville, GANPI 1417154956

Payments from drug & device makers

$1,534in general payments, 2019–2025

Across 38 payments — averaging $40.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$441
  • AbbVie$267
  • Alcon$206
  • Glaukos Corporation$119
  • Notal Vision, Inc.$118
  • Johnson & Johnson Surgical Vision, Inc.$114
  • plus $269 from 8 others

What the payments were for

  • Speaking & faculty fees$1188%
  • Food & beverage$1,41692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,534 in reported general payments places this provider in the 40th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$89,602
Medicare patients
341
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine89$78,425
MieboPerfluorohexyloctane/Pf26$25,328
XiidraLifitegrast15$14,482
Cyclosporine25$5,230
IlevroNepafenac14$5,085
Prednisolone Acetate144$4,616
Bromfenac Sodium27$3,188
MoxifloxacinMoxifloxacin Hcl126$2,459
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$1,863
Latanoprost281$1,828
Azelastine Hcl35$1,667
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat55$773
Timolol Maleate35$715
Brimonidine Tartrate33$482
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha28$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$267$78,42589 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$45$39,81041 claims
NovartisIlevro$14$5,08514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →